Ceftriaxone (marketed as Rocephin and generics)
MedSun: Newsletter #36, May 2009

FDA notified healthcare professionals of an update to a previous alert on the interaction of ceftriaxone with calcium-containing products, based on previously reported fatal cases in neonates. Based on the results of new studies FDA now recommends that ceftriaxone and calcium-containing products may be used concomitantly in patients over 28 days of age, using the precautionary recommendations noted because the risk of precipitation is low in this population.

Additional Information:

Ceftriaxone (marketed as Rocephin and generics). FDA MedWatch Alert. April 14, 2009.
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm136533.htm

Information for Healthcare Professionals: Ceftriaxone (marketed as Rocephin and generics). April 21, 2009.
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084263.ht


MedSun Newsletters are available at www.fda.gov/cdrh/medsun